132 related articles for article (PubMed ID: 37014172)
21. Medium-term oncological outcomes in a large cohort of men treated with either focal or hemi-ablation using high-intensity focused ultrasonography for primary localized prostate cancer.
Stabile A; Orczyk C; Hosking-Jervis F; Giganti F; Arya M; Hindley RG; Dickinson L; Allen C; Punwani S; Jameson C; Freeman A; McCartan N; Montorsi F; Briganti A; Ahmed HU; Emberton M; Moore CM
BJU Int; 2019 Sep; 124(3):431-440. PubMed ID: 30753756
[TBL] [Abstract][Full Text] [Related]
22. A comparison of time taken to return to baseline erectile function following focal and whole gland ablative therapies for localized prostate cancer: A systematic review.
Faure Walker NA; Norris JM; Shah TT; Yap T; Cathcart P; Moore CM; Ahmed HU; Emberton M; Minhas S
Urol Oncol; 2018 Feb; 36(2):67-76. PubMed ID: 29277585
[TBL] [Abstract][Full Text] [Related]
23. New treatments for localized prostate cancer.
Marberger M; Carroll PR; Zelefsky MJ; Coleman JA; Hricak H; Scardino PT; Abenhaim LL
Urology; 2008 Dec; 72(6 Suppl):S36-43. PubMed ID: 19095127
[TBL] [Abstract][Full Text] [Related]
24. Evolution and outcomes of 3 MHz high intensity focused ultrasound therapy for localized prostate cancer during 15 years.
Thüroff S; Chaussy C
J Urol; 2013 Aug; 190(2):702-10. PubMed ID: 23415962
[TBL] [Abstract][Full Text] [Related]
25. Focal therapy compared to radical prostatectomy for non-metastatic prostate cancer: a propensity score-matched study.
Shah TT; Reddy D; Peters M; Ball D; Kim NH; Gomez EG; Miah S; Evans DE; Guillaumier S; van Rossum PSN; Van Son MJ; Hosking-Jervis F; Dudderidge T; Hindley R; Emara A; McCracken S; Greene D; Nigam R; McCartan N; Valerio M; Minhas S; Afzal N; Lewi H; Ogden C; Persad R; Virdi J; Moore CM; Arya M; Emberton M; Ahmed HU; Winkler M
Prostate Cancer Prostatic Dis; 2021 Jun; 24(2):567-574. PubMed ID: 33504940
[TBL] [Abstract][Full Text] [Related]
26. Primary cryotherapy for localised or locally advanced prostate cancer.
Jung JH; Risk MC; Goldfarb R; Reddy B; Coles B; Dahm P
Cochrane Database Syst Rev; 2018 May; 5(5):CD005010. PubMed ID: 29845595
[TBL] [Abstract][Full Text] [Related]
27. Magnetic Resonance Imaging and Targeted Biopsies Compared to Transperineal Mapping Biopsies Before Focal Ablation in Localised and Metastatic Recurrent Prostate Cancer After Radiotherapy.
Shah TT; Kanthabalan A; Otieno M; Pavlou M; Omar R; Adeleke S; Giganti F; Brew-Graves C; Williams NR; Grierson J; Miah H; Emara A; Haroon A; Latifoltojar A; Sidhu H; Clemente J; Freeman A; Orczyk C; Nikapota A; Dudderidge T; Hindley RG; Virdi J; Arya M; Payne H; Mitra A; Bomanji J; Winkler M; Horan G; Moore CM; Emberton M; Punwani S; Ahmed HU
Eur Urol; 2022 Jun; 81(6):598-605. PubMed ID: 35370021
[TBL] [Abstract][Full Text] [Related]
28. Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer.
Wilt TJ; MacDonald R; Rutks I; Shamliyan TA; Taylor BC; Kane RL
Ann Intern Med; 2008 Mar; 148(6):435-48. PubMed ID: 18252677
[TBL] [Abstract][Full Text] [Related]
29. External validation of biochemical recurrence definition to predict oncologic outcomes following focal therapy for localized prostate cancer using high intensity focused ultrasound.
Mattlet A; Limani K; Alexandre P; Hawaux E; Abou Zahr R; Aoun F; Diamand R
Prostate; 2023 Dec; 83(16):1564-1571. PubMed ID: 37574824
[TBL] [Abstract][Full Text] [Related]
30. Focal therapy for localized prostate cancer: a critical appraisal of rationale and modalities.
Eggener SE; Scardino PT; Carroll PR; Zelefsky MJ; Sartor O; Hricak H; Wheeler TM; Fine SW; Trachtenberg J; Rubin MA; Ohori M; Kuroiwa K; Rossignol M; Abenhaim L;
J Urol; 2007 Dec; 178(6):2260-7. PubMed ID: 17936815
[TBL] [Abstract][Full Text] [Related]
31. Focal salvage high-intensity focused ultrasound in radiorecurrent prostate cancer.
Kanthabalan A; Peters M; Van Vulpen M; McCartan N; Hindley RG; Emara A; Moore CM; Arya M; Emberton M; Ahmed HU
BJU Int; 2017 Aug; 120(2):246-256. PubMed ID: 28258616
[TBL] [Abstract][Full Text] [Related]
32. Focal cryotherapy for clinically unilateral, low-intermediate risk prostate cancer in 73 men with a median follow-up of 3.7 years.
Bahn D; de Castro Abreu AL; Gill IS; Hung AJ; Silverman P; Gross ME; Lieskovsky G; Ukimura O
Eur Urol; 2012 Jul; 62(1):55-63. PubMed ID: 22445223
[TBL] [Abstract][Full Text] [Related]
33. Comparative Analysis of Partial Gland Ablation and Radical Prostatectomy to Treat Low and Intermediate Risk Prostate Cancer: Oncologic and Functional Outcomes.
Garcia-Barreras S; Sanchez-Salas R; Sivaraman A; Barret E; Secin F; Nunes-Silva I; Linares-Espinós E; Rozet F; Galiano M; Cathelineau X
J Urol; 2018 Jan; 199(1):140-146. PubMed ID: 28823768
[TBL] [Abstract][Full Text] [Related]
34. Prostate Specific Antigen Criteria to Diagnose Failure of Cancer Control following Focal Therapy of Nonmetastatic Prostate Cancer Using High Intensity Focused Ultrasound.
Huber PM; Afzal N; Arya M; Boxler S; Dudderidge T; Emberton M; Guillaumier S; Hindley RG; Hosking-Jervis F; Leemann L; Lewi H; McCartan N; Moore CM; Nigam R; Odgen C; Persad R; Thalmann GN; Virdi J; Winkler M; Ahmed HU
J Urol; 2020 Apr; 203(4):734-742. PubMed ID: 31928408
[TBL] [Abstract][Full Text] [Related]
35. Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.
Kupelian PA; Katcher J; Levin HS; Klein EA
Int J Radiat Oncol Biol Phys; 1997 Mar; 37(5):1043-52. PubMed ID: 9169811
[TBL] [Abstract][Full Text] [Related]
36. PSA nadir as a predictive factor for biochemical disease-free survival and overall survival following whole-gland salvage HIFU following radiotherapy failure.
Shah TT; Peters M; Kanthabalan A; McCartan N; Fatola Y; van der Voort van Zyp J; van Vulpen M; Freeman A; Moore CM; Arya M; Emberton M; Ahmed HU
Prostate Cancer Prostatic Dis; 2016 Sep; 19(3):311-6. PubMed ID: 27431499
[TBL] [Abstract][Full Text] [Related]
37. High Intensity Focused Ultrasound Hemigland Ablation for Prostate Cancer: Initial Outcomes of a United States Series.
Abreu AL; Peretsman S; Iwata A; Shakir A; Iwata T; Brooks J; Tafuri A; Ashrafi A; Park D; Cacciamani GE; Kaneko M; Duddalwar V; Aron M; Palmer S; Gill IS
J Urol; 2020 Oct; 204(4):741-747. PubMed ID: 32898975
[TBL] [Abstract][Full Text] [Related]
38. Primary Whole-gland Ablation for the Treatment of Clinically Localized Prostate Cancer: A Focal Therapy Society Best Practice Statement.
Deivasigamani S; Kotamarti S; Rastinehad AR; Salas RS; de la Rosette JJMCH; Lepor H; Pinto P; Ahmed HU; Gill I; Klotz L; Taneja SS; Emberton M; Lawrentschuk N; Wysock J; Feller JF; Crouzet S; Kumar M P; Seguier D; Adams ES; Michael Z; Abreu A; Jack Tay K; Ward JF; Shinohara K; Katz AE; Villers A; Chin JL; Stricker PD; Baco E; Macek P; Ahmad AE; Chiu PKF; Crawford ED; Rogers CG; Futterer JJ; Rais-Bahrami S; Robertson CN; Hadaschik B; Marra G; Valerio M; Chong KT; Kasivisvanathan V; Tan WP; Lomas D; Walz J; Guimaraes GC; Mertziotis NI; Becher E; Finelli A; Kasraeian A; Lebastchi AH; Vora A; Rosen MA; Bakir B; Arcot R; Yee S; Netsch C; Meng X; de Reijke TM; Tan YG; Regusci S; Benjamin TGR; Olivares R; Noureldin M; Bianco FJ; Sivaraman A; Kim FJ; Given RW; Dason S; Sheetz TJ; Shoji S; Schulman A; Royce P; Shah TT; Scionti S; Salomon G; Laguna P; Tourinho-Barbosa R; Aminsharifi A; Cathelineau X; Gontero P; Stabile A; Grummet J; Ledbetter L; Graton M; Stephen Jones J; Polascik TJ;
Eur Urol; 2023 Dec; 84(6):547-560. PubMed ID: 37419773
[TBL] [Abstract][Full Text] [Related]
39. Intraprostatic Cancer Recurrence following Radical Radiotherapy on Transperineal Template Mapping Biopsy: Implications for Focal Ablative Salvage Therapy.
Kanthabalan A; Arya M; Freeman A; Mitra AV; Payne H; Peters M; Shah TT; Emberton M; Ahmed HU
J Urol; 2020 Nov; 204(5):950-955. PubMed ID: 32602770
[TBL] [Abstract][Full Text] [Related]
40. A multi-centre prospective development study evaluating focal therapy using high intensity focused ultrasound for localised prostate cancer: The INDEX study.
Dickinson L; Ahmed HU; Kirkham AP; Allen C; Freeman A; Barber J; Hindley RG; Leslie T; Ogden C; Persad R; Winkler MH; Emberton M;
Contemp Clin Trials; 2013 Sep; 36(1):68-80. PubMed ID: 23774040
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
